Liquidia's stock dropped sharply after a federal court ruled that its key drug, YUTREPIA, infringes patents held by United Therapeutics related to treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). This ruling forces Liquidia to remove the PH-ILD indication from YUTREPIA's label, limiting its market potential and creating uncertainty about future sales. Liquidia plans to appeal the decision while United Therapeutics seeks an injunction. The dispute has significantly impacted Liquidia's stock performance, with shares falling as much as 57%, reflecting investor concerns over the drug's commercial outlook.
Liquidia's patent ruling news is presented with Pluang's Health-sector market data as of Oct 02, 2026 18:51 WIB. Of 100 priced Health-sector US stocks tradable on Pluang, 71 rose and 26 fell today. Notable movers include DGX (Quest Diagnostics Inc) at USD 228.58 with a -1.09% change and a typical hold time of 55 days, CYTK (Cytokinetics Inc) at USD 66.33 with a +1.08% change and a typical hold time of 19 days, and SNN (Smith & Nephew plc) at USD 26.30 with a -1.05% change and a typical hold time of 120 days. The largest daily price change among these is CYTK's +1.08%.
Scotiabank has lowered its price target for Comcast from $29.00 to $27.50 as the stock faces significant challenges, including a 12-year low trading price and increased competition from services like Starlink. Comcast's share price has dropped 58% si...
UBS has maintained its Buy rating on PepsiCo but lowered the price target from $159 to $145 following a nearly 8% drop in PepsiCo's stock over the past month. Investors are awaiting the company's Q3 earnings report on October 8, with analysts expecti...
UBS has maintained a Neutral rating on Nike stock following the company's fiscal first-quarter revenue falling short of estimates and its announcement of layoffs. Nike's shares dropped over 7% amid weak earnings guidance and expectations of further s...
Acuity Inc. reported strong fiscal Q4 earnings with adjusted EPS of $5.77, beating analyst estimates despite net sales of $1.244 billion falling just short of consensus. Operating profit rose 25.7% to $227 million, and operating margin expanded to 18...
Analysts from Robert W. Baird and Bank of America have lowered their price targets for Fair Isaac (FICO) due to changes in mortgage rules by Fannie Mae and Freddie Mac. These changes favor alternative credit scoring models like VantageScore, potentia...
